The US government program that allows safety net providers to purchase drugs at deep discounts is probably not what most American voters have in mind when they say drug pricing is a top issue. But the 340B program has been a rare area of consistent focus – and actual sustained change – in the Trump Administration.
Four years into Donald Trump’s unpredictable Presidency, one constant theme has been headlines about executive action on drug pricing.
From his pre-Inauguration Day declaration that the industry is “getting away with murder,” through the 2018 Rose Garden unveiling of...